Title Epidemiological and clinical characteristics of cancer patients with COVID-19: A systematic review and meta-analysis of global data
Authors Kong, Xiangyi
Qi, Yihang
Huang, Junjie
Zhao, Yang
Zhan, Yongle
Qin, Xuzhen
Qi, Zhihong
Atanda, Adejare (Jay)
Zhang, Lei
Wang, Jing
Fang, Yi
Jia, Peng
Golozar, Asieh
Zhang, Lin
Jiang, Yu
Affiliation Chinese Acad Med Sci, Natl Canc Ctr, Dept Breast Surg Oncol, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China
Peking Union Med Coll, Beijing 100021, Peoples R China
Chinese Univ Hong Kong, Fac Med, Jockey Club Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China
Peking Univ, George Inst Global Hlth, Hlth Sci Ctr, Beijing, Peoples R China
Univ Melbourne, WHO Collaborating Ctr Implementat Res Prevent & C, Melbourne, Vic 3010, Australia
Chinese Acad Med Sci, Sch Populat Med & Publ Hlth, Beijing 100021, Peoples R China
Chinese Acad Med Sci, Peking Union Med Coll Hosp, Clin Lab, Beijing 100730, Peoples R China
Peking Union Med Coll, Beijing 100730, Peoples R China
Morgan State Univ, Sch Community Hlth & Policy, Baltimore, MD 21239 USA
Xi An Jiao Tong Univ, China Australia Joint Res Ctr Infect Dis, Sch Publ Hlth, Hlth Sci Ctr, Xian 710061, Shanxi, Peoples R China
Alfred Hlth, Melbourne Sexual Hlth Ctr, Melbourne, Vic, Australia
Monash Univ, Fac Med, Cent Clin Sch, Melbourne, Vic, Australia
Zhengzhou Univ, Coll Publ Hlth, Dept Epidemiol & Biostat, Zhengzhou 450001, Henan, Peoples R China
Hong Kong Polytech Univ, Dept Land Surveying & Geoinformat, Hong Kong, Peoples R China
Int Inst Spatial Lifecourse Epidemiol ISLE, Hong Kong, Peoples R China
Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
Regeneron Pharmaceut, New York, NY USA
Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia
Victorian Comprehens Canc Ctr, Ctr Canc Res, Melbourne, Vic, Australia
Keywords CORONAVIRUS DISEASE 2019
MORTALITY
OUTCOMES
CHINA
COMORBIDITIES
MULTICENTER
MANAGEMENT
PNEUMONIA
WUHAN
RISK
Issue Date 28-Jun-2021
Publisher CANCER LETTERS
Abstract There are minimal data regarding the prevalence of cancer in patients with coronavirus disease 2019 (COVID-19), as well as the incidence of severe illness and rate of mortality in COVID-19 patients with cancer. PubMed, Embase, Cochrane Library, and Web of Science were systematically searched, from database inception to July 15, 2020, for studies of patients with COVID-19 that included information regarding comorbid cancer. In total, 109 eligible global studies were included in this systematic review. Ninety studies with 94,845 COVID-19 patients, among which 4106 exhibited comorbid cancer, were included in the meta-analysis regarding prevalence of comorbid cancer. Twenty-three studies with 71,969 COVID-19 patients, among which 4351 with comorbid cancer had severe illness or death, were included in the meta-analysis. The overall prevalence of cancer among COVID-19 patients was 0.07 (95% CI 0.05-0.09). The cancer prevalence in COVID-19 patients was higher in Europe (0.22, 95% CI 0.17-0.28) than in the Asia-Pacific region (0.04, 95% CI 0.03-0.06) or North America (0.05, 95% CI 0.04-0.06). The cancer prevalence in COVID-19 patients aged >60 years was 0.10 (95% CI 0.07-0.14), while the prevalence among patients aged <= 60 years was 0.05 (95% CI 0.03-0.06). The pooled prevalence of severe illness among COVID-19 patients with cancer was 0.34 (95% CI 0.26-0.42) and the pooled mortality rate of COVID-19 patients with cancer was 0.20 (95% CI 0.16-0.25). Pooled incidences of severe illness among COVID-19 patients with cancer from Asia Pacific, Europe, and North America were 0.38 (95% CI 0.24-0.52), 0.39 (95% CI 0.25-0.53), and 0.26 (95% CI 0.20-0.31), respectively; pooled mortality rates from the Asia-Pacific region, Europe, and North America were 0.17 (95% CI 0.10-0.24), 0.26 (95% CI 0.18-0.35), and 0.19 (95% CI 0.13-0.25), respectively.
URI http://hdl.handle.net/20.500.11897/613004
ISSN 0304-3835
DOI 10.1016/j.canlet.2021.02.012
Indexed SCI(E)
Appears in Collections: 医学部待认领

Files in This Work
There are no files associated with this item.

Web of Science®


0

Checked on Last Week

Scopus®



Checked on Current Time

百度学术™


0

Checked on Current Time

Google Scholar™





License: See PKU IR operational policies.